Delonix polymeric nanoparticles with isotretinoin effectively treat acne by targeting hair follicles and reducing skin irritation.
9 citations
,
November 2004 in “Bioorganic & Medicinal Chemistry Letters” New compounds were made that effectively block enzymes related to prostate issues and hair loss.
January 2025 in “Reactions Weekly” November 2024 in “Reactions Weekly” May 2023 in “Reactions Weekly”
25 citations
,
April 2014 in “Journal of Scientific and Innovative Research” Tridax procumbens may help treat diabetes.
2 citations
,
May 2012 in “Indian drugs” Finasteride, a hair loss treatment, works better and is more stable when delivered through specially prepared gels, leading to increased hair growth.
3 citations
,
August 2013 in “Stem cells” Certain inhibitors applied to the skin can promote hair growth by maintaining a key hair growth signal.
1 citations
,
August 2025 in “Journal of Neonatal Surgery” The nanogel with Ciclopirox Olamine is a promising treatment for skin yeast infections.
January 2022 in “eJournal Kedokteran Indonesia” Both treatments are similarly effective, but paclitaxel-carboplatin is cheaper and has more severe side effects.
July 2025 in “Actas Dermo-Sifiliográficas” Trichodynia is a challenging scalp condition to treat, needing gentle care and more research for better solutions.
14 citations
,
March 2022 in “Journal of Biomedical Science” Cyanidin 3-O-arabinoside may help treat a common form of hair loss by protecting cells against aging and improving cell function.
September 2024 in “Cermin Dunia Kedokteran” Improving medical training is key to eradicating frambusia by 2030.
32 citations
,
December 2003 in “Planta” Hypaphorine from a fungus changes the internal structure of Eucalyptus root hairs, stopping their growth.
42 citations
,
February 1996 in “Journal of Investigative Dermatology” Polyamines, especially spermidine, are essential for hair growth.
April 2019 in “Journal of Investigative Dermatology” Non-coding RNA boosts retinoic acid production and signaling, aiding regeneration.
June 2023 in “Clinical Cosmetic and Investigational Dermatology” Pentoxifylline effectively improves pretibial pruritic papular dermatitis.
12 citations
,
December 2022 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.
2 citations
,
November 1990 in “International Journal of Dermatology” Albendazole can cause hair loss, and piroxicam can cause fixed drug eruption.
December 2012 in “http://isrctn.org/>”
August 2018 in “Journal of The American Academy of Dermatology” Different treatments for skin conditions were found to be effective and generally safe, with biologics recommended as the first choice for generalized pustular psoriasis.
13 citations
,
September 2022 in “International Journal of Molecular Sciences” Five existing drugs may help fight Swine Acute Diarrhea Syndrome Coronavirus.
25 citations
,
July 2013 in “Actas Dermo-Sifiliográficas” Acitretin is effective for severe psoriasis and can be used long-term due to no immunosuppression, but must be carefully monitored for side effects and is not for pregnant women.
March 2025 in “Biomedical & Pharmacology Journal” Valproic acid is effective but often causes side effects like weight gain and hair loss, so personalized treatment is needed.
1 citations
,
February 2025 in “International Journal of Dermatology” Abrocitinib may effectively treat Lichen Planopilaris.
Blocking 5α-reductase can reduce sleep deprivation-related behavioral issues in rats.
November 2023 in “International Journal of Pharmaceutics” The new delivery system improves treatment for hair loss by enhancing drug absorption and effectiveness.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 is generally safe for treating alopecia areata.
April 2017 in “Actas urológicas españolas” 5-alpha reductase inhibitors increase the risk of sexual dysfunction in patients treating enlarged prostate but not in those treating hair loss.
May 2026 in “RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218” This review analyzes recent scientific evidence on the neuroendocrine and metabolic impacts of chronic use of 5-alpha reductase inhibitors, focusing on Post-Finasteride Syndrome (PFS). The study, based on eight high-impact studies from 2021 to 2026, highlights PFS as a multisystemic condition linked to the use of 5-ARIs, with reports of refractory sexual dysfunction and mood disorders in young patients. The inhibition of enzymes in the central nervous system suppresses the synthesis of active metabolites like allopregnanolone, leading to GABAergic dysregulation and excitotoxicity. Metabolically, the suppression of dihydrotestosterone is associated with insulin resistance, non-alcoholic fatty liver disease, Type 2 Diabetes Mellitus, and changes in gut microbiota. Genetic polymorphisms in the SRD5A2 gene and epigenetic changes, such as DNA methylation of the androgen receptor, contribute to the chronicity of symptoms. The findings suggest that PFS extends beyond transient side effects, emphasizing the need for personalized medicine models and strengthened informed consent protocols to mitigate persistent biopsychosocial risks.